+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Direct-acting Antiviral Drug Market - Global Forecast to 2030- Product Image
Direct-acting Antiviral Drug Market - Global Forecast to 2030- Product Image
Sale

Direct-acting Antiviral Drug Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 182 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5311192
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Direct-acting Antiviral Drug Market grew from USD 12.18 billion in 2024 to USD 13.87 billion in 2025. It is expected to continue growing at a CAGR of 13.31%, reaching USD 25.79 billion by 2030.

Direct-acting antivirals have redefined the treatment paradigm for chronic viral infections by targeting specific stages of the viral life cycle to achieve sustained virologic response. These therapies interrupt replication processes with high precision, transforming previously intractable diseases into manageable conditions. Amid rising global prevalence of hepatitis B and C, the pace of innovation in antiviral drug development has accelerated, driven by breakthroughs in molecular design and clinical validation. As healthcare systems prioritize cost-effective and patient-centric solutions, direct-acting antivirals have emerged as a cornerstone of therapeutic portfolios, delivering shorter treatment durations, improved safety profiles, and higher cure rates.

In parallel, regulatory bodies have streamlined approval pathways for therapies demonstrating significant clinical benefit, further stimulating industry investment. Strategic alliances among biopharmaceutical companies, diagnostic firms, and contract research organizations have also intensified, fostering an integrated ecosystem that spans discovery, development, and delivery. As we explore the transformative shifts shaping this market, it is essential to recognize the interplay of scientific innovation, policy dynamics, and competitive forces that will determine the trajectory of direct-acting antiviral drug adoption worldwide.

Transformative Shifts in the Direct-Acting Antiviral Landscape

Over the past decade, the direct-acting antiviral landscape has undergone several transformative shifts. First, the transition from interferon-based regimens to oral small-molecule inhibitors has marked a watershed in patient convenience and tolerability. Next, the emergence of pan-genotypic NS5A and protease inhibitors has simplified treatment algorithms, enabling standardized protocols across diverse patient populations. Meanwhile, advances in companion diagnostics-ranging from lab-based assays to point-of-care platforms-have enhanced real-time viral genotyping and resistance profiling, thereby optimizing therapeutic selection.

Concurrently, streamlined regulatory pathways such as accelerated approval and breakthrough designations have compressed development timelines, allowing novel compounds to reach the clinic faster. This momentum has spurred a wave of fixed-dose combinations that integrate multiple mechanisms of action into single-entity formulations, supporting adherence and reducing the potential for viral rebound. Moreover, the maturation of real-world evidence platforms has provided critical insights into long-term efficacy, safety, and pharmacoeconomic impacts, guiding formulary decisions and reimbursement policies. Together, these shifts have elevated market expectations, demanding strategic agility from both established pharmaceutical leaders and emerging biotech innovators.

Cumulative Impact of U.S. Tariffs in 2025

In 2025, the United States implemented a series of tariffs on active pharmaceutical ingredients and finished formulations imported from key global suppliers, responding to supply-chain vulnerabilities exposed during recent public health emergencies. These measures have triggered cost pressures across the value chain, particularly for therapies that rely on offshore manufacturing of polymerase inhibitors and protease inhibitors. As raw material costs increase, manufacturers have recalibrated sourcing strategies-ranging from nearshoring to dual-sourcing arrangements-to preserve margin integrity while maintaining supply continuity.

Payers and providers are also adjusting to higher acquisition costs through more stringent formulary management and value-based contracting, incentivizing patient adherence and outcome-driven pricing. Several companies have negotiated risk-sharing agreements that tie reimbursement to sustained virologic response rates, mitigating the financial impact of tariff-induced price fluctuations. Simultaneously, contract manufacturing organizations have accelerated capacity expansions in North America to reduce exposure to import levies and shorten lead times. Overall, the cumulative impact of these tariffs has catalyzed a broader reassessment of global supply-chain design, underscoring the importance of agility, diversification, and local manufacturing resilience.

Key Segmentation Insights

Segmentation by drug type reveals that combination therapies command a premium share of treatment protocols, harnessing NS5A inhibitors alongside protease or polymerase inhibitors to disrupt multiple replication pathways. Within capsules, injectables, and tablets, patient preference for oral tablets remains dominant, yet long-acting injectable formulations are gaining traction for select regimens that target low-adherence populations. Virus type segmentation underscores the dual market opportunity for hepatitis C, where high cure rates drive demand, and hepatitis B, where functional cures remain an aspirational goal.

Patient demographics influence regimen selection: adults comprise the bulk of current prescriptions, geriatrics present unique safety and pharmacokinetic considerations, and pediatrics represent an underserved segment poised for growth as pediatric trials advance. Distribution channels adapt accordingly-hospital pharmacies lead inpatient administrations, retail pharmacies support chronic outpatient therapy, and online pharmacies cater to digital health models that emphasize home delivery. When examining treatment duration, short-term therapies have become the standard for hepatitis C, whereas long-term therapy persists in hepatitis B management, reflecting divergent clinical objectives.

Mechanism of action segmentation distinguishes direct virus action agents from immune-mediated approaches, highlighting an evolution toward combination regimens that synergize antiviral potency with host response modulation. Fixed-dose combinations simplify dosing and reduce pill burden compared to single-entity formulations, particularly in complex genotype profiles. The level of intervention-primary versus secondary therapy-drives market uptake, with first-line regimens focusing on maximal efficacy and second-line options reserved for resistant or relapsed cases. Patient compliance segmentation underscores the need for high-adherence strategies, as low or moderate adherence correlates with virologic failure and potential resistance development.

Therapeutic end users span inpatient settings, where intensive monitoring supports initiation of complex regimens, to outpatient clinics that manage follow-up and maintenance phases. Companion diagnostics, including diagnostic kits, lab testing, and point-of-care platforms, underpin precision medicine initiatives by informing viral genotyping and resistance mapping. The drug development stage landscape is robust, with numerous candidates in clinical trials and post-market surveillance programs generating real-world evidence. Finally, regulatory pathway segmentation-accelerated approval, breakthrough therapy, and orphan drug designation-continues to shape time-to-market for innovative direct-acting antivirals.

Key Regional Insights

In the Americas, established healthcare infrastructures and favorable reimbursement frameworks support rapid uptake of innovative antiviral regimens, with real-world evidence studies validating cost-effectiveness in diverse payer environments. Europe, Middle East & Africa regions face heterogeneity in healthcare financing and regulatory alignment; however, pan-European initiatives aim to harmonize access through joint procurement and value-based agreements. Meanwhile, Asia-Pacific markets present a dynamic mix of emerging economies and highly developed systems: China’s localized manufacturing capacity and national hepatitis elimination goals accelerate domestic adoption, while Japan and Australia prioritize precision diagnostics and clade-specific therapeutics.

Regional supply-chain resilience varies, prompting strategic investments in local production sites across each geography. In the Americas, onshoring API and formulation facilities has reduced tariff exposure and shortened lead times. In EMEA, partnerships between multinational corporations and regional contract manufacturers have fostered capacity expansion in underserved markets. Asia-Pacific’s diversified supplier base has mitigated risk but also introduced complexity in quality assurance standards, driving demand for harmonized regulatory oversight. Across all regions, digital health platforms and telemedicine initiatives are expanding access to direct-acting antiviral therapies, particularly in remote and rural settings.

Key Company Insights

Global industry leaders have intensified R&D investments and strategic collaborations to maintain competitive advantage. Boehringer Ingelheim International GmbH has advanced its pipeline with next-generation NS5A inhibitor combinations designed for pan-genotypic coverage. Bristol-Myers Squibb Company has leveraged its expertise in immune-mediated action to develop companion immunotherapeutic approaches alongside direct antivirals. Cipla Limited’s focus on affordable generic formulations has broadened access in emerging markets, while EVERSANA’s integrated commercialization services have accelerated market entry for novel therapies.

F. Hoffmann-La Roche Ltd. continues to optimize its fixed-dose regimens through stability enhancements and patient-centric packaging. Merck & Co., Inc. has pursued strategic alliances to diversify its portfolio across both polymerase and protease inhibitor classes. Novartis AG is exploring adaptive trial designs to expedite regulatory approvals under breakthrough therapy pathways. Pfizer Inc. is enhancing its digital diagnostics capabilities, integrating point-of-care testing into treatment protocols. Takeda Pharmaceutical Company Limited emphasizes pharmacoeconomic studies to support value-based contracting, and Viatris Inc. focuses on scalable manufacturing platforms to meet global demand for high-adherence formulations.

Actionable Recommendations for Industry Leaders

To navigate the evolving antiviral landscape, industry leaders should prioritize supply-chain diversification by establishing regional production hubs and dual-sourcing agreements. They must invest in digital health solutions that support adherence monitoring and telemedicine consultations, thereby driving higher sustained virologic response rates. Strengthening partnerships with diagnostic providers will enable seamless integration of lab testing and point-of-care assays, optimizing patient selection and minimizing treatment failures.

Engaging in outcome-based contracting with payers will align pricing structures with real-world performance, reducing budgetary pressures and demonstrating the long-term value of curative therapies. Companies should also explore innovative regulatory pathways, such as accelerated approval and orphan drug designation, to bring breakthrough treatments to market more swiftly. Finally, fostering cross-sector alliances-among pharma, biotech, and digital health firms-will catalyze the development of combination regimens that address both direct viral inhibition and host immune modulation, setting a new standard for therapeutic efficacy.

Conclusion: Charting a Path Toward Viral Eradication

Direct-acting antivirals stand at the forefront of modern therapeutic innovation, offering the potential to cure chronic viral infections and alleviate global disease burdens. As the market adapts to tariff-induced cost pressures, evolving segmentation demands, and regional access disparities, stakeholders must adopt agile strategies that balance scientific rigor with operational resilience. By harnessing precision diagnostics, digital adherence tools, and outcome-based pricing models, organizations can enhance patient outcomes while safeguarding profitability.

Looking ahead, sustained success will hinge on the ability to anticipate policy shifts, streamline development workflows, and cultivate collaborative ecosystems that bridge research, manufacturing, and patient care. This holistic approach will not only accelerate the delivery of life-changing therapies but also reinforce trust among providers, payers, and patients, ultimately advancing the collective goal of viral eradication.

Market Segmentation & Coverage

This research report categorizes the Direct-acting Antiviral Drug Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Combination Therapy
  • NS5A Inhibitors
  • Polymerase Inhibitors
  • Protease Inhibitors
  • Capsules
  • Injectables
  • Tablets
  • Hepatitis B
  • Hepatitis C
  • Adults
  • Geriatrics
  • Pediatrics
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Long-Term Therapy
  • Short-Term Therapy
  • Direct Virus Action
  • Immune-Mediated Action
  • Fixed-Dose Combinations
  • Single-Entity Formulations
  • Primary Therapy
  • Secondary Therapy
  • High Adherence
  • Low Adherence
  • Moderate Adherence
  • Inpatients
  • Outpatients
  • Diagnostic Kits
  • Lab Testing
  • Point-Of-Care Testing
  • Clinical Trials
  • Post-Market Surveillance
  • Preclinical
  • Accelerated Approval
  • Breakthrough Therapy
  • Orphan Drug Designation

This research report categorizes the Direct-acting Antiviral Drug Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Direct-acting Antiviral Drug Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Boehringer Ingelheim International GmbH.
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • EVERSANA
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Viatris Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Direct-acting Antiviral Drug Market, by Drug Type
8.1. Introduction
8.2. Combination Therapy
8.3. NS5A Inhibitors
8.4. Polymerase Inhibitors
8.5. Protease Inhibitors
9. Direct-acting Antiviral Drug Market, by Product Form
9.1. Introduction
9.2. Capsules
9.3. Injectables
9.4. Tablets
10. Direct-acting Antiviral Drug Market, by Virus Type
10.1. Introduction
10.2. Hepatitis B
10.3. Hepatitis C
11. Direct-acting Antiviral Drug Market, by Patient Demographics
11.1. Introduction
11.2. Adults
11.3. Geriatrics
11.4. Pediatrics
12. Direct-acting Antiviral Drug Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
13. Direct-acting Antiviral Drug Market, by Treatment Duration
13.1. Introduction
13.2. Long-Term Therapy
13.3. Short-Term Therapy
14. Direct-acting Antiviral Drug Market, by Mechanism Of Action
14.1. Introduction
14.2. Direct Virus Action
14.3. Immune-Mediated Action
15. Direct-acting Antiviral Drug Market, by Dosage Form
15.1. Introduction
15.2. Fixed-Dose Combinations
15.3. Single-Entity Formulations
16. Direct-acting Antiviral Drug Market, by Level Of Intervention
16.1. Introduction
16.2. Primary Therapy
16.3. Secondary Therapy
17. Direct-acting Antiviral Drug Market, by Patient Compliance
17.1. Introduction
17.2. High Adherence
17.3. Low Adherence
17.4. Moderate Adherence
18. Direct-acting Antiviral Drug Market, by Therapeutic End User
18.1. Introduction
18.2. Inpatients
18.3. Outpatients
19. Direct-acting Antiviral Drug Market, by Companion Diagnostics
19.1. Introduction
19.2. Diagnostic Kits
19.3. Lab Testing
19.4. Point-Of-Care Testing
20. Direct-acting Antiviral Drug Market, by Drug Development Stage
20.1. Introduction
20.2. Clinical Trials
20.3. Post-Market Surveillance
20.4. Preclinical
21. Direct-acting Antiviral Drug Market, by Regulatory Pathway
21.1. Introduction
21.2. Accelerated Approval
21.3. Breakthrough Therapy
21.4. Orphan Drug Designation
22. Americas Direct-acting Antiviral Drug Market
22.1. Introduction
22.2. Argentina
22.3. Brazil
22.4. Canada
22.5. Mexico
22.6. United States
23. Asia-Pacific Direct-acting Antiviral Drug Market
23.1. Introduction
23.2. Australia
23.3. China
23.4. India
23.5. Indonesia
23.6. Japan
23.7. Malaysia
23.8. Philippines
23.9. Singapore
23.10. South Korea
23.11. Taiwan
23.12. Thailand
23.13. Vietnam
24. Europe, Middle East & Africa Direct-acting Antiviral Drug Market
24.1. Introduction
24.2. Denmark
24.3. Egypt
24.4. Finland
24.5. France
24.6. Germany
24.7. Israel
24.8. Italy
24.9. Netherlands
24.10. Nigeria
24.11. Norway
24.12. Poland
24.13. Qatar
24.14. Russia
24.15. Saudi Arabia
24.16. South Africa
24.17. Spain
24.18. Sweden
24.19. Switzerland
24.20. Turkey
24.21. United Arab Emirates
24.22. United Kingdom
25. Competitive Landscape
25.1. Market Share Analysis, 2024
25.2. FPNV Positioning Matrix, 2024
25.3. Competitive Analysis
25.3.1. Boehringer Ingelheim International GmbH.
25.3.2. Bristol-Myers Squibb Company
25.3.3. Cipla Limited
25.3.4. EVERSANA
25.3.5. F. Hoffmann-La Roche Ltd.
25.3.6. Merck & Co., Inc.
25.3.7. Novartis AG
25.3.8. Pfizer Inc.
25.3.9. Takeda Pharmaceutical Company Limited
25.3.10. Viatris Inc.
26. ResearchAI
27. ResearchStatistics
28. ResearchContacts
29. ResearchArticles
30. Appendix
List of Figures
FIGURE 1. DIRECT-ACTING ANTIVIRAL DRUG MARKET MULTI-CURRENCY
FIGURE 2. DIRECT-ACTING ANTIVIRAL DRUG MARKET MULTI-LANGUAGE
FIGURE 3. DIRECT-ACTING ANTIVIRAL DRUG MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT FORM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY VIRUS TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY VIRUS TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TREATMENT DURATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TREATMENT DURATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 20. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 22. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY LEVEL OF INTERVENTION, 2024 VS 2030 (%)
FIGURE 24. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY LEVEL OF INTERVENTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT COMPLIANCE, 2024 VS 2030 (%)
FIGURE 26. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT COMPLIANCE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC END USER, 2024 VS 2030 (%)
FIGURE 28. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMPANION DIAGNOSTICS, 2024 VS 2030 (%)
FIGURE 30. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMPANION DIAGNOSTICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG DEVELOPMENT STAGE, 2024 VS 2030 (%)
FIGURE 32. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG DEVELOPMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGULATORY PATHWAY, 2024 VS 2030 (%)
FIGURE 34. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGULATORY PATHWAY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 35. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 36. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 37. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 38. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 39. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 40. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 41. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 42. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 43. DIRECT-ACTING ANTIVIRAL DRUG MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 44. DIRECT-ACTING ANTIVIRAL DRUG MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DIRECT-ACTING ANTIVIRAL DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5A INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY POLYMERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY LONG-TERM THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SHORT-TERM THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DIRECT VIRUS ACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY IMMUNE-MEDIATED ACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY FIXED-DOSE COMBINATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SINGLE-ENTITY FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY LEVEL OF INTERVENTION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRIMARY THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SECONDARY THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT COMPLIANCE, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIGH ADHERENCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY LOW ADHERENCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MODERATE ADHERENCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC END USER, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INPATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY OUTPATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DIAGNOSTIC KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY LAB TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY POST-MARKET SURVEILLANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGULATORY PATHWAY, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ACCELERATED APPROVAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY BREAKTHROUGH THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ORPHAN DRUG DESIGNATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY LEVEL OF INTERVENTION, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT COMPLIANCE, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC END USER, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGULATORY PATHWAY, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY LEVEL OF INTERVENTION, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT COMPLIANCE, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC END USER, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGULATORY PATHWAY, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY LEVEL OF INTERVENTION, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT COMPLIANCE, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC END USER, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGULATORY PATHWAY, 2018-2030 (USD MILLION)
TABLE 100. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 101. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
TABLE 102. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 103. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 104. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 106. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 107. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 108. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY LEVEL OF INTERVENTION, 2018-2030 (USD MILLION)
TABLE 109. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT COMPLIANCE, 2018-2030 (USD MILLION)
TABLE 110. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC END USER, 2018-2030 (USD MILLION)
TABLE 111. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 112. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 113. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGULATORY PATHWAY, 2018-2030 (USD MILLION)
TABLE 114. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 115. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
TABLE 116. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 117. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 118. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 120. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 121. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 122. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY LEVEL OF INTERVENTION, 2018-2030 (USD MILLION)
TABLE 123. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT COMPLIANCE, 2018-2030 (USD MILLION)
TABLE 124. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC END USER, 2018-2030 (USD MILLION)
TABLE 125. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 126. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 127. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGULATORY PATHWAY, 2018-2030 (USD MILLION)
TABLE 128. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 129. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
TABLE 130. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 131. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 132. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 133. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 134. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 135. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 136. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY LEVEL OF INTERVENTION, 2018-2030 (USD MILLION)
TABLE 137. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT COMPLIANCE, 2018-2030 (USD MILLION)
TABLE 138. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC END USER, 2018-2030 (USD MILLION)
TABLE 139. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 140. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 141. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGULATORY PATHWAY, 2018-2030 (USD MILLION)
TABLE 142. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 143. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 144. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
TABLE 145. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 146. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 147. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 149. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 150. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 151. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY LEVEL OF INTERVENTION, 2018-2030 (USD MILLION)
TABLE 152. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT COMPLIANCE, 2018-2030 (USD MILLION)
TABLE 153. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC END USER, 2018-2030 (USD MILLION)
TABLE 154. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 155. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 156. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGULATORY PATHWAY, 2018-2030 (USD MILLION)
TABLE 157. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 158. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 159. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
TABLE 160. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 161. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 162. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 164. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 165. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 166. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY LEVEL OF INTERVENTION, 2018-2030 (USD MILLION)
TABLE 167. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT COMPLIANCE, 2018-2030 (USD MILLION)
TABLE 168. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC END USER, 2018-2030 (USD MILLION)
TABLE 169. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 170. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 171. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGULATORY PATHWAY, 2018-2030 (USD MILLION)
TABLE 172. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 173. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
TABLE 174. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 175. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 176. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 178. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 179. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 180. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY LEVEL OF INTERVENTION, 2018-2030 (USD MILLION)
TABLE 181. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT COMPLIANCE, 2018-2030 (USD MILLION)
TABLE 182. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC END USER, 2018-2030 (USD MILLION)
TABLE 183. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 184. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 185. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGULATORY PATHWAY, 2018-2030 (USD MILLION)
TABLE 186. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 187. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
TABLE 188. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 189. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 190. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 192. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 193. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 194. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY LEVEL OF INTERVENTION, 2018-2030 (USD MILLION)
TABLE 195. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT COMPLIANCE, 2018-2030 (USD MILLION)
TABLE 196. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC END USER, 2018-2030 (USD MILLION)
TABLE 197. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 198. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 199. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGULATORY PATHWAY, 2018-2030 (USD MILLION)
TABLE 200. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 201. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
TABLE 202. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 203. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 204. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 205. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 206. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 207. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 208. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY LEVEL OF INTERVENTION, 2018-2030 (USD MILLION)
TABLE 209. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT COMPLIANCE, 2018-2030 (USD MILLION)
TABLE 210. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC END USER, 2018-2030 (USD MILLION)
TABLE 211. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 212. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 213. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGULATORY PATHWAY, 2018-2030 (USD MILLION)
TABLE 214. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 215. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
TABLE 216. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 217. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 218. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 220. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 221. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 222. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY LEVEL OF INTERVENTION, 2018-2030 (USD MILLION)
TABLE 223. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT COMPLIANCE, 2018-2030 (USD MILLION)
TABLE 224. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC END USER, 2018-2030 (USD MILLION)
TABLE 225. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 226. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 227. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGULATORY PATHWAY, 2018-2030 (USD MILLION)
TABLE 228. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 229. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
TABLE 230. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 231. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 232. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 233. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 234. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 235. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 236. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY LEVEL OF INTERVENTION, 2018-2030 (USD MILLION)
TABLE 237. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT COMPLIANCE, 2018-2030 (USD MILLION)
TABLE 238. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC END USER, 2018-2030 (USD MILLION)
TABLE 239. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 240. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 241. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGULATORY PATHWAY, 2018-2030 (USD MILLION)
TABLE 242. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 243. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
TABLE 244. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 245. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 246. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 247. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 248. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 249. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 250. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY LEVEL OF INTERVENTION, 2018-2030 (USD MILLION)
TABLE 251. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT COMPLIANCE, 2018-2030 (USD MILLION)
TABLE 252. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC END USER, 2018-2030 (USD MILLION)
TABLE 253. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 254. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 255. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGULATORY PATHWAY, 2018-2030 (USD MILLION)
TABLE 256. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 257. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
TABLE 258. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 259. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 260. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 261. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 262. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 263. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 264. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY LEVEL OF INTERVENTION, 2018-2030 (USD MILLION)
TABLE 265. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT COMPLIANCE, 2018-2030 (USD MILLION)
TABLE 266. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC END USER, 2018-2030 (USD MILLION)
TABLE 267. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 268. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 269. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGULATORY PATHWAY, 2018-2030 (USD MILLION)
TABLE 270. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 271. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
TABLE 272. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 273. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 274. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 275. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 276. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 277. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 278. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY LEVEL OF INTERVENTION, 2018-2030 (USD MILLION)
TABLE 279. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT COMPLIANCE, 2018-2030 (USD MILLION)
TABLE 280. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC END USER, 2018-2030 (USD MILLION)
TABLE 281. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 282. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 283. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGULATORY PATHWAY, 2018-2030 (USD MILLION)
TABLE 284. TAIWAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 285. TAIWAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
TABLE 286. TAIWAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 287. TAIWAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 288. TAIWAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. TAIWAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 290. TAIWAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 291. TAIWAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 292. TAIWAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY LEVEL OF INTERVENTION, 2018-2030 (USD MILLION)
TABLE 293. TAIWAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT COMPLIANCE, 2018-2030 (USD MILLION)
TABLE 294. TAIWAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC END USER, 2018-2030 (USD MILLION)
TABLE 295. TAIWAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 296. TAIWAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 297. TAIWAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGULATORY PATHWAY, 2018-2030 (USD MILLION)
TABLE 298. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 299. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
TABLE 300. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 301. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 302. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 303. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 304. THAIL

Companies Mentioned

  • Boehringer Ingelheim International GmbH.
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • EVERSANA
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Viatris Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Direct-acting Antiviral Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Direct-acting Antiviral Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 181 Pages
  • Global
From
Antiviral Therapeutics Market by Drug, Therapy, Distribution - Global Forecast 2025-2030 - Product Image

Antiviral Therapeutics Market by Drug, Therapy, Distribution - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Antiviral Drugs Market by Drug Type, Therapeutics, End Use - Global Forecast 2025-2030 - Product Image

Antiviral Drugs Market by Drug Type, Therapeutics, End Use - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From
Oral Antiviral Market 2024 Edition: Market Size, Trends, Opportunities and Forecast by Drug Class, Indication, Distribution Channel, Region, By Country: 2020-2030 - Product Image

Oral Antiviral Market 2024 Edition: Market Size, Trends, Opportunities and Forecast by Drug Class, Indication, Distribution Channel, Region, By Country: 2020-2030

  • Report
  • 296 Pages
  • Global
From
Antiviral Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Antiviral Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Drug Pipelines
  • 150 Pages
  • Global
From

About the Direct Acting Antiviral Drug Market

Direct-acting antiviral drugs (DAAs) represent a class of pharmaceuticals specifically targeting viruses at the molecular level to prevent their proliferation. Within the broader category of infectious diseases drugs, DAAs are used mainly for the treatment of viral infections such as hepatitis C and can have a transformative effect by providing high cure rates and shortened treatment durations compared to older interferon-based therapies. These drugs act directly on viral enzymes and proteins critical to the viral life cycle, disrupting processes such as viral RNA replication and protein production. Their development has been a major advance in the therapeutic management of chronic viral infections, leading to substantial improvements in patient outcomes. The DAA market is characterized by innovation and rapid development of new therapies that offer improved efficacy and safety profiles. Key players in the direct-acting antiviral drug market include Gilead Sciences, Merck & Co., AbbVie Inc., and Bristol-Myers Squibb. Gilead Sciences, for example, is known for its portfolio of DAAs for the treatment of hepatitis C, which has redefined the standard of care in this therapeutic area. These companies are continuously engaged in the research and development of new DAAs that promise to enhance patient care and expand therapeutic options for various viral infections. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.